The impact of IRF8 mutation on HLA-DM expression appears to be stronger in human DLBCL than in murine B cell lymphomas whereas CD74 defect is clearer in the latter. This evidence concerns the gene HLA-DMA and B-cell non-Hodgkin lymphoma.